Jackson Square Partners LLC Purchases 2,094 Shares of IQVIA Holdings Inc. $IQV

Jackson Square Partners LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,461 shares of the medical research company’s stock after purchasing an additional 2,094 shares during the period. Jackson Square Partners LLC’s holdings in IQVIA were worth $2,594,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd grew its holdings in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the first quarter worth $33,000. Trust Co. of Toledo NA OH acquired a new stake in IQVIA in the second quarter valued at $39,000. J.Safra Asset Management Corp lifted its holdings in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after buying an additional 169 shares during the period. Finally, Larson Financial Group LLC grew its position in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after buying an additional 144 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $210.50 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a fifty day moving average price of $199.38 and a 200-day moving average price of $176.07. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $225.00. The firm has a market cap of $35.85 billion, a price-to-earnings ratio of 28.88, a PEG ratio of 2.36 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of several recent research reports. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Cowen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Monday. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, Barclays increased their target price on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $239.94.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.